Evidence map›Paper›PMID 36500674›Full record

ArticleMolecules (Basel, Switzerland)2022

HPLC with Fluorescence and Photodiode Array Detection for Quantifying Capmatinib in Biological Samples: Application to In Vivo and In Vitro Studies.

Aref Zayed, Sana'a A Jaber, Jomana Al Hroot, Sahar Hawamdeh, Nehad M Ayoub, Nidal A Qinna

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Aref ZayedDepartment of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science and Technology (JUST), Irbid 22110, Jordan.ORCID 0000-0003-0211-1866
Sana'a A JaberDepartment of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science and Technology (JUST), Irbid 22110, Jordan.
Jomana Al HrootDepartment of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science and Technology (JUST), Irbid 22110, Jordan.
Sahar HawamdehDepartment of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science and Technology (JUST), Irbid 22110, Jordan.
Nehad M AyoubDepartment of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology (JUST), Irbid 22110, Jordan.ORCID 0000-0003-2284-4370
Nidal A QinnaUniversity of Petra Pharmaceutical Center (UPPC), Faculty of Pharmacy and Medical Sciences, University of Petra, Amman 11196, Jordan.ORCID 0000-0002-9628-6036
Jordan University of Science and Technology · JOPetra University · JO

Funding

Jordan University of Science and Technology 20220039
6 · The paper itself

Abstract

Capmatinib, a recently approved tyrosine kinase inhibitor, is used for the treatment of non-small cell lung cancer. We describe two new HPLC methods for capmatinib quantification in vivo and in vitro. HPLC with a fluorescence detection method was used to quantify capmatinib in plasma for the first time. The method was successfully applied in a pharmacokinetic study following a 10 mg/kg oral dose of capmatinib given to rats. The chromatographic separation was performed using a Eurospher II 100-3 C18H (50 × 4 mm, 3 µm) column and a mobile phase containing 10 mM of ammonium acetate buffer (pH 5.5): acetonitrile (70:30,

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAnimalsBenzamidesChromatography, High Pressure LiquidChromatography, LiquidHumansImidazolesRatsReproducibility of ResultsTandem Mass SpectrometryTriazinesBenzamidescapmatinibImidazolesTriazinescapmatinibfluorescenceHPLCmetabolic stabilitymethod developmentmicrosomespharmacokineticsrat plasmatyrosine kinase inhibitor

Identifiers

PMID36500674
PMCPMC9738601
OpenAlexW4311545144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.